Golden Financier
  • Investing
  • Stock
  • Latest News
  • Editor’s Pick
  • Economy

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
    Popular Topics
    • Morgan Stanley foresees volatility for Match, Bumble in Q2 as turnaround remains elusive
    • US needs ‘more negotiations’ with India on trade ahead of Aug 1 tariff deadline, Greer says
    • India overtakes China as top smartphone exporter to US amid shifting supply chains
    • Stellantis stock slides as reinstated guidance underwhelms investors
    • Floating LNG terminals overcome hurdles, set for nearly fourfold expansion by 2035
    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions
    Golden Financier
    • Investing
    • Stock
    • Latest News
    • Editor’s Pick
    • Economy
    • Economy

    Moderna stock rallies on HHS lawsuit news: analyst says negative sentiment reversing

    • July 9, 2025
    • admin

    Shares of Moderna surged 9.5% on Tuesday to $32.75 in a notable reversal of recent bearish sentiment, buoyed by legal developments and renewed investor focus on the company’s potential vaccine pipeline.

    The uptick follows a turbulent period for the pharmaceutical firm, which has seen its stock tumble more than 80% over the past year.

    On Monday, a coalition of major medical organizations filed a lawsuit against US Health Secretary Robert F. Kennedy Jr. and the Department of Health and Human Services, challenging recent decisions to remove healthy children and pregnant women from the COVID-19 vaccine schedule.

    The plaintiffs argued the changes represent a clear threat to public health and demanded the court declare the moves unlawful.

    The lawsuit, led by Richard H. Hughes IV—a vaccine law expert from George Washington University—accuses Kennedy of attempting to dismantle public confidence in vaccines.

    “The secretary’s intentions are clear,” said Hughes. “He aims to destroy vaccines.”

    The plaintiffs include the American Public Health Association, the American Academy of Pediatrics, and other top health bodies.

    Analyst sees gain as “reversal of peak negative investor sentiment”

    B. Riley Securities analyst Mayank Mamtani said Moderna’s share movement likely reflects “a reversal of peak negative investor sentiment,” pointing to the recent lawsuit and upcoming vaccine advisory committee meetings as potential short-term catalysts.

    The news may have helped rebalance sentiment in a market that had heavily shorted the stock.

    Other vaccine makers also posted gains, with Pfizer rising 1.6% and Novavax climbing 6.7%.

    The latter benefited from recent late-stage study results tied to its COVID-influenza combination and standalone flu vaccines, Mamtani said.

    Why is MRNA struggling?

    Despite the day’s gains, Moderna’s outlook remains difficult.

    The company is still down 22% year-to-date and 72% over the past 12 months.

    Investor confidence was shaken last year after Moderna announced weaker vaccine sales in Europe, attributed to a renegotiated contract between the EU and Pfizer-BioNTech.

    The news led to a steep sell-off following the company’s second-quarter earnings.

    Financially, Moderna’s revenue has dropped sharply, from $18.9 billion in 2022 to $3.1 billion over the past year, an 83% decline.

    Sales are forecast to drop further to around $2.1 billion in 2025 as demand for COVID-19 vaccines continues to wane and the company adjusts to a seasonal vaccine model.

    Short interest remains high despite the recent bounce.

    As of mid-June, 18.6% of Moderna’s float was sold short, making it the second most-shorted stock in the S&P 500, down only slightly from May’s peak levels.

    In January, Moderna cut its 2025 revenue forecast by $1 billion and pushed back its break-even expectations by two years, citing delays in its product development pipeline.

    The post Moderna stock rallies on HHS lawsuit news: analyst says negative sentiment reversing appeared first on Invezz


    admin

    Previous Article
    • Economy

    China’s push to end oversupply could forge a new class of market champions: JPMorgan

    • July 9, 2025
    • admin
    View Post
    Next Article
    • Stock

    European stocks soar higher on hopes of trade deal: FTSE up 0.8%, DAX jumps 0.4%

    • July 10, 2025
    • admin
    View Post

      Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


      By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
      Popular Topics
      • Morgan Stanley foresees volatility for Match, Bumble in Q2 as turnaround remains elusive
      • US needs ‘more negotiations’ with India on trade ahead of Aug 1 tariff deadline, Greer says
      • India overtakes China as top smartphone exporter to US amid shifting supply chains
      • Stellantis stock slides as reinstated guidance underwhelms investors
      • Floating LNG terminals overcome hurdles, set for nearly fourfold expansion by 2035

      Input your search keywords and press Enter.